COVID-19 Vaccine Provider Call

May 2022

Please place your name, and provider in the chat.
Agenda

- State Data
- Communications & Outreach
- COVID Administration Guidance
- Vaccine Storage & Handling Updates
- Vaccine Ordering & Distribution
- OSIIS Updates
- Questions/Suggestions
- Looking Forward
Statewide COVID-19 Vaccine Administration (as of 5/3/2022)

2,221,785 people have received at least 1 dose* of the COVID-19 vaccine

1,883,584 people are fully vaccinated** with the COVID-19 vaccine

782,827 people have received a 3rd dose^ or booster dose^^ of the COVID-19 vaccine

58,754 people have received a 4th dose or 2nd booster dose of the COVID-19 vaccine

Across Oklahoma, a total of 4,818,870 COVID-19 vaccine doses have been administered since 12/14/2020

* Refers to eligible individuals (ages 5 years+) receiving Pfizer and Moderna COVID-19 vaccines and/or receiving single shot of J&J/Janssen Vaccine; ** Refers to eligible individuals (ages 5 years+) fully vaccinated after receiving either Pfizer and/or Moderna COVID-19 vaccines (both doses) and/or receiving single shot of J&J/Janssen Vaccine; ^3rd dose (Pfizer or Moderna) for individuals moderately to severely immunocompromised to be received at least 28 days after a second dose; ^^Booster dose for individuals 65+ or certain other adults at high risk of severe COVID-19 to be received at least six months after completion of the primary mRNA vaccine series or two months after receiving single dose of J&J/Janssen vaccine.

Note: Total vaccines administered does not include doses administered by federal entities (Bureau of Prisons, Veterans Health, Indian Health Service, or Department of Defense).

Communications & Outreach

Christa Copeland, MHR
IMMS Communications Manager
We will soon email a survey to participants who have not ordered or administered COVID-19 vaccine in the last 3 months.

If you receive the survey, your completion of that survey will be vital to your continued participation in the COVID-19 vaccine program.

If you have ordered and/or administered COVID-19 vaccine the last 3 months, this should not apply to you.

However, we may continue to send surveys regarding ongoing participation, so please check your email and please participate should you receive one in the future.
COVID Vaccine Administration Guidance

Anna Anthony, RN, BSN
Immunization Service, Public Health Nurse
<table>
<thead>
<tr>
<th>Vaccine</th>
<th>0 month</th>
<th>1 month</th>
<th>2 month</th>
<th>3 month</th>
<th>4 month</th>
<th>5 month</th>
<th>6 month</th>
<th>7 month</th>
<th>8 month</th>
<th>9 month</th>
<th>10 month</th>
<th>11 month</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer-BioNTech (ages 5–11 years)</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt; dose (3 weeks after 1&lt;sup&gt;st&lt;/sup&gt; dose)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pfizer-BioNTech (ages 12 years and older)</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt; dose&lt;sup&gt;†&lt;/sup&gt; (3-8 weeks after 1&lt;sup&gt;st&lt;/sup&gt; dose)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderna (ages 18 years and older)</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt; dose&lt;sup&gt;‡&lt;/sup&gt; (4-8 weeks after 1&lt;sup&gt;st&lt;/sup&gt; dose)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Janssen (ages 18 years and older)</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose</td>
<td>Booster dose&lt;sup&gt;§&lt;/sup&gt; (at least 2 months after 1&lt;sup&gt;st&lt;/sup&gt; dose)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Note: Timeline is approximate. Intervals of 3 months or fewer are converted into weeks per the formula “1 month = 4 weeks.” Intervals of 4 months or more are converted into calendar months.*

*See Guidance for COVID-19 vaccination for people who are moderately or severely immunocompromised for schedule for people who are moderately or severely immunocompromised.

†An 8-week interval may be optimal for some people ages 12 years and older, especially for males aged 12–39 years. A shorter interval (3 weeks for Pfizer-BioNTech; 4 weeks for Moderna) between the first and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is increased concern about COVID-19 community levels or an individual’s higher risk for severe disease.

‡A booster dose is not currently authorized for people ages 5–11 years. For people ages 12–17 years, only Pfizer-BioNTech can be used. An mRNA COVID-19 vaccine is preferred over the Janssen COVID-19 Vaccine for booster vaccination of people ages 18 years and older.

§People ages 18–49 years who received Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive an mRNA COVID-19 booster dose at least 4 months after the Janssen booster dose. People ages 50 years and older may choose to receive a second booster dose if it has been at least 4 months after the first booster dose.
Pfizer (Adult and Adolescent)

• **Primary Series**
  
  • *Non-Immunocompromised Adults*: **Two** doses (0.3 mL) 3 weeks apart for 12 years of age and older.
  
  • *Non-Immunocompromised Children*: **Two** doses (0.2 ml) 3 weeks apart for 5 to 11 years of age.
  
  • *Immunocompromised Individuals*: Three doses.
    
    • Third dose of primary series (0.3 ml) **at least** 28 days following the second dose for 12 years of age and older who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.
    
    • Third dose (0.2 mL) **at least** 28 days following the second dose for 5-11 years of age who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

• **Booster Doses**

  • A single Pfizer-BioNTech COVID-19 Vaccine booster dose (0.3 mL) may be administered intramuscularly at least 5 months after completing the primary series to individuals **12** years of age and older.
  
  • A second single Pfizer-BioNTech COVID-19 Vaccine booster dose (0.3 ml) at least 4 months after the first booster dose for adults aged 50 years and older **OR** immunocompromised individuals **12** years of age.
Pfizer Packaging and Dosage

• Three vaccine presentations are in circulation with different preparation and storage guidelines: Purple Cap, Gray Cap, and Orange Cap.

• Providers are encouraged to administer any Purple Cap vaccine in their inventory before Gray Cap.

• Children ages 5 through 11 years old should only be vaccinated with the Dilute Before Use Orange Cap vaccine formula (“Age 5y to <12y” on vial label).
  • It is critical to ensure children 5 through 11 years old only receive the Orange Cap vaccine in order to avoid potential age-related adverse events including product preparation issues, incorrect dose administered, and underdosage.

• All Pfizer vaccines are given based on age.
  • For example, patients who turn 12 between dose 1 and 2 will get 12+ formulation.

• See link provided for detailed information: Home | CVDvaccine-US.com
Pfizer Vaccination Schedule

Vaccination Schedule for ImmunoCOMPETENT Persons

<table>
<thead>
<tr>
<th>Ages</th>
<th>Pfizer-BioNTech COVID-19 Vaccine EUA Fact Sheet Schedule</th>
</tr>
</thead>
</table>
| 5 through 11 Years* | - 1st Dose: 3 weeks  
|                  | - 2nd Dose: 3 weeks *A booster dose for children 5 through 11 years of age is not currently authorized |
| 12 through 49 Years | - 1st Dose: 3 weeks**  
|                  | - 2nd Dose: At least 5 months  
|                  | - 1st Booster |
| 50 Years of Age and Older | - 1st Dose: 3 weeks**  
|                  | - 2nd Dose: At least 5 months  
|                  | - 1st Booster  
|                  | - 2nd Booster |

**According to the CDC Interim Clinical Considerations, an 8-week primary series interval may be optimal for some people ages 12 years and older, especially for males ages 12–19 years. The authorized interval (3 weeks for the Pfizer-BioNTech COVID-19 Vaccine) between the first and second doses remains the recommended interval for:  
- People who are moderately to severely immunocompromised  
- Adults ages 65 years and older  
- Others who need the fullest possible protection to be achieved sooner due to increased concern about community transmission or an individual’s higher risk for severe disease.
Pfizer Vaccination Schedule

Vaccination Schedule for ImmunoCOMPROMISED Persons

Immunocompromise refers to individuals who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.¹

### Ages

<table>
<thead>
<tr>
<th>Pfizer-BioNTech COVID-19 Vaccine EUA Fact Sheet Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 through 11 Years†</td>
</tr>
<tr>
<td>1st Dose</td>
</tr>
<tr>
<td>3 weeks</td>
</tr>
<tr>
<td>2nd Dose</td>
</tr>
<tr>
<td>At least 28 Days</td>
</tr>
<tr>
<td>3rd Dose</td>
</tr>
<tr>
<td>*A booster dose for children 5 through 11 years of age is not currently authorized</td>
</tr>
</tbody>
</table>

| 12 Years of Age and Older                             |
| 1st Dose                                               |
| 2nd Dose                                               |
| 3rd Dose                                               |
| 1st Booster                                            |
| 2nd Booster                                            |
| At least 5 months**                                    |
| At least 4 months                                      |
| ≥3 months per CDC**                                    |

**While the vaccine EUA Fact Sheets provide for a first booster dose after 5 months, according to the CDC Interim Clinical Considerations, a first booster dose is recommended at least 3 months after the third dose in the primary series for people who are moderately or severely immunocompromised.²

Reminder: Pfizer does not make recommendations for use of its vaccine outside of the FDA label.

<table>
<thead>
<tr>
<th>Description</th>
<th>Dilute Before Use</th>
<th>Do Not Dilute</th>
<th>Dilute Before Use</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age Group</strong></td>
<td>12 years and older</td>
<td>12 years and older</td>
<td>5 through 11 years</td>
</tr>
<tr>
<td><strong>Vial Cap Color and Label with Color Border</strong></td>
<td>PURPLE</td>
<td>GRAY</td>
<td>ORANGE</td>
</tr>
</tbody>
</table>

### Storage Conditions

<table>
<thead>
<tr>
<th>Storage Condition</th>
<th>Dilute Before Use</th>
<th>Do Not Dilute</th>
<th>Dilute Before Use</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ULT Freezer (-90°C to -60°C)</strong></td>
<td>12 months*</td>
<td>12 months**</td>
<td>12 months**</td>
</tr>
<tr>
<td><strong>Freezer (-25°C to -15°C)</strong></td>
<td>2 weeks</td>
<td><strong>DO NOT STORE</strong></td>
<td><strong>DO NOT STORE</strong></td>
</tr>
<tr>
<td><strong>Refrigerator (2°C to 8°C)</strong></td>
<td>1 month</td>
<td>10 weeks</td>
<td>10 weeks</td>
</tr>
<tr>
<td><strong>Room Temperature (8°C to 25°C)</strong></td>
<td>2 hours prior to dilution (including any thaw time)</td>
<td>12 hours prior to first puncture (including any thaw time)</td>
<td>12 hours prior to dilution (including any thaw time)</td>
</tr>
<tr>
<td><strong>After First Puncture (2°C to 25°C)</strong></td>
<td>Discard after 6 hours</td>
<td>Discard after 12 hours</td>
<td>Discard after 12 hours</td>
</tr>
</tbody>
</table>

For more complete information and guidance, visit: [Home (cvdvaccine-us.com)](http://cvdvaccine-us.com)
• **Primary Series**
  
  • **Not Immunocompromised** Adults: **Two** doses (0.5 mL each) 3-8 weeks apart.
  
  • **Immunocompromised** Adults: **Three** doses (0.5 mL each).
    
    • To be administered **at least 28 days** following the second dose is authorized for 18 years of age and older who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

• **Booster Doses**

  • Single dose (0.25 mL) **at least 5** months after completing the primary series for anyone 18+ years.
  
  • Additional Single dose (0.25 mL) **at least 4** months after the previous booster for adults 50+ years OR immunocompromised individuals 18+ years.
Primary Series
• One dose (0.5 mL each).

Booster Doses
• Recommend that people receive an mRNA booster at 2 months after initial dose.
• A second booster dose may be administered to those 50yrs and older OR immunocompromised individuals 18yrs+ at least 4 months after their booster.

Changes to the J&J/Janssen EUA (as of May 5, 2022)
• Janssen COVID-19 Vaccine EUA Fact Sheet for Healthcare Providers (fda.gov)
• Pages 4-5, 13: Immune Thrombocytopenia

Federal Allocation has resumed for a limited time. Any order placed for the minimum amount (100) will be direct shipped. Orders requesting less than the minimum amount will be fulfilled by local County Health Departments.
• Providers need to remain aware of expiry date of vaccines in their inventory.
• The expiration date can be obtained by entering the lot number from the carton or vial using the website www.vaxcheck.jnj
# Mixing and Matching Boosters

<table>
<thead>
<tr>
<th>Who Should Get a Booster</th>
<th>When to Get a Booster</th>
<th>Which Booster can you get</th>
</tr>
</thead>
<tbody>
<tr>
<td>* Everyone 12+</td>
<td>* At least 5 months after completing your primary COVID 19 Vaccination Series</td>
<td><em>18+: any mRNA COVID vaccine</em></td>
</tr>
<tr>
<td>* Everyone 18+</td>
<td>* At least 5 months after completing your primary COVID 19 Vaccination Series</td>
<td><em>18+: any mRNA COVID vaccine</em></td>
</tr>
<tr>
<td>* Everyone 18+</td>
<td>* At least 2 months after completing your primary COVID 19 Vaccination Series</td>
<td><em>18+: any mRNA COVID vaccine</em></td>
</tr>
</tbody>
</table>

**COVID Vaccine Received:**

<table>
<thead>
<tr>
<th>PFIZER</th>
<th>MODERNA</th>
<th>JANSSEN</th>
</tr>
</thead>
</table>

- *non-mRNA can be used to booster in special circumstances, please consult Primary Care Physician*
Co-Administration

• You may administer COVID-19 and Influenza vaccines without regard to timing (both live, attenuated and non-live influenza vaccines).

• This includes administration of COVID-19 and Influenza vaccines on the same day, as well as co-administration at any time interval.

• Administer the COVID-19 vaccines and vaccines that may be more likely to cause a local reaction (i.e., adjuvanted influenza vaccines) in different limbs, if possible.

• When deciding whether to co-administer other vaccine(s) with COVID-19 vaccine, consider:
  • Whether the patient is behind or at risk of becoming behind on recommended vaccines
  • The patient’s risk of vaccine-preventable disease
  • The reactogenicity profile of the vaccines
  • The likelihood of avoiding a missed opportunity to vaccinate
Vaccine Storage and Handling

Sonja Claborn and Tina Shatto, Immunization Field Consultants
Best Practice for Inventory Management

• To reduce waste, providers should be aware of vaccine in their inventory that are nearing expiration dates and prioritize their administration.

• Providers should enroll in the CDC Code Management Service to access the most up to date Expiration Information for all Vaccines.
  • Vaccine Lot Number and Expiration Date Webpage
  • Click the "Register" button in the upper right-hand corner to complete the registration form to request access.

• Moderna and J&J Vaccine Expiration Lookup & Reference Information:
  • Moderna Vial Expiration Data Look Up Tool
  • J&J Expiration Date Look Up Tool
Inventory Update Required
Vaccine Finder, OSIIS

Failure to maintain an updated inventory may impact vaccine orders.

• Per the CDC, starting May 1st providers are required to update inventory in Vaccine Finder on a *weekly* basis.

• Inventory will be listed by vaccine name and age designation, *not* cap color.

• Training Videos and Guides:
  • [https://www.vaccines.gov/covid-provider-resources/](https://www.vaccines.gov/covid-provider-resources/)

• Step By Step Instructions:

• For assistance in updating Vaccine Finder or OSIIS please call Immunization Services at (405) 426-8580.
Vaccine Inventory Adjustment: On-Hand Expired Vaccines

- When reconciling inventory, check that your facility has no expired inventory on hand.
  - Navigate to the Vaccine Inventory On-Hand screen by selecting:
    - Inventory > Vaccines > On-Hand from the left-hand menu.
  - Change the Status from On-Hand to Depleted/Expired
  - Locate the Filter tab
  - Locate the vaccine inventory item requiring an inventory adjustment.
  - Click the corresponding Action button and select Adjustment.
  - Complete the following required fields:
    - Date (enter the actual date on which the inventory was wasted)
    - Reason (select Vtrcks Other)
    - Modification (if a value does not default, select Add or Subtract to make the corresponding adjustment)
    - Doses Adjusted (enter the number of doses wasted for the selected reason)
    - Comments (Expired)
  - Click the Create button.
  - Click the On-Hand menu item to return to the Vaccine Inventory On-Hand screen where you can verify the inventory was adjusted correctly.
  - See attached video on Resources/Tools (Slide #40)
Wastage

Do not return unused, open, spoiled, or expired COVID19 vaccines to manufacturers, distributors, OSDH, or CHD.

Discard all expired, wasted, and opened vials in the sharps container at the end of each day. Do not put open vials back into the fridge: adjust in OSIIS and discard at the end of the day.

COVID-19 vaccine program requirements include reporting wastage (unused, open, spoiled, or expired) into OSIIS. Please follow the Wastage tip sheet to report COVID-19 vaccine wastage.

After recording, the vaccine must be disposed in accordance with Oklahoma regulations and processes to dispose of regulated medical waste.
Updated Pfizer Data Logger: Controlant SAGA Logger

- Pfizer vaccine shippers are transitioning to an updated data logger from Controlant called "SAGA Logger."
- The SAGA Logger will provide improved performance for monitoring and reporting during shipment.
- The interactive LCD tracker display shows current temperatures and the minimum and maximum temperatures of the shipper contents during transit.
- The new SAGA Logger is slightly larger in size, and, as with the previous logger, requires return shipping in the packaging materials provided with your order.
- Key improvements to this device include:
  - Enhanced location accuracy with Wi-Fi.
  - Utilization of the 4G cellular network.
  - Interactive LCD display with an improved user interface.
  - 150 days of backup storage when no cloud is available.
  - Longer battery life.
  - Improved data transmission capability.

![Controlant SAGA Logger](image)
Vaccine Expiration Dates

Important for all vaccines:
• Check the expiration dates upon receiving vaccines.
• Due to increased studies about stability data, check the expiration date again later (before administering vaccines and during weekly reconciliation).
• Please note that Moderna expiration extensions only apply to vaccines that have not been thawed or refrigerated.
• Reminder: Janssen should never be stored in the freezer or ultracold.
• How to check expiration dates?
  • Scan QR code and it will take you to the website showing the expiration date.
  • Locate lot number on the package and type into the website.
    • Janssen website
    • Moderna website
• Pfizer: Purple Cap follow Extension guideline
  Orange and Gray Cap follow Expiration Calculation
The Food & Drug Administration announced the approval of a shelf-life extension for the Johnson & Johnson’s Janssen COVID-19 vaccine for an additional 5 months.

• The shelf-life of this vaccine has been updated from 6 months to 11 months.

• This shelf-life extension applies to all inventory dated to expire on March 7, 2022 or later.

• Vaccine dated prior to March 7, 2022, should be disposed of according to state and local regulation and reported as waste based on your COVID-19 provider agreement.

Vaccine providers should visit the Janssen COVID-19 Vaccine Expiry Checker webpage to confirm expiration dates. This shelf-life extension applies to refrigerated vials of J&J/Janssen COVID-19 vaccine that have been held in accordance with the manufacturer’s storage conditions.
Pfizer Vaccine Expiration Extension

- The date printed on Orange Cap and Gray Cap Pfizer vaccine vials indicate the manufacture date and **NOT** the expiration date.
  - The original expiration date was 6 months from the manufacturer date.
  - The expiration date has now been extended to 12 months from the date of manufacture (**ONLY** while held at ULT frozen).

- The OSIIS homepage displays a table displaying the current manufacturing dates with the 6-month extension.

- If you have this vaccine in your inventory and it has been stored frozen (ULT), you will need to update the expiration date in OSIIS by selecting the Action button next to the vaccine in inventory > selecting Edit > and entering the new expiration date > and selecting Update.

- **Check the expiration date before administering or discarding the vaccine.** If you see a wrong expiration date in OSIIS, please update it in OSIIS inventory and in your systems.
• Regardless of storage conditions, **Purple Cap** vaccine should not be used past the 12-month expiry.
• Vials with expiry dates of October 2021-March 2022* (printed on the label) reflects the 6-month expiry and may remain in use for 3 months beyond the printed date, *for a total of 9 months* if vials are maintained in approved storage conditions (-90°C to -60°C, -130°F to -76°F).

| Ages 12 years and older DILUTE BEFORE USE **Purple Cap** |
|-----------------|-------------------|
| Printed Expiry Date | Updated Expiry Date |
| 10/2021       | 30-Apr-2022       |
| 11/2021       | 31-May-2022       |
| 12/2021       | 30-Jun-2022       |
| 01/2022       | 31-Jul-2022       |
| 02/2022       | 31-Aug-2022       |
| 03/2022       | 30-Sep-2022       |
| 07/2022       | 31-Oct-2022       |
| 08/2022       | 30-Nov-2022       |
| 09/2022       | 31-Dec-2022       |
| 10/2022       | 31-Jan-2023       |
| 11/2022       | 28-Feb-2023       |

• Regardless of storage condition, **Orange Cap** and **Gray Cap** vaccine vials should not be used after 12 months from the *date of manufacture* printed on the vial and cartons.

Ages 5 through 11 **DILUTE BEFORE USE** **Orange Cap** and **Ages 12 years and older DO NOT DILUTE** **Gray Cap**

<table>
<thead>
<tr>
<th>Printed Manufacturing Date</th>
<th>12-Month Expiry Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/2021</td>
<td>31-May-2022</td>
</tr>
<tr>
<td>07/2021</td>
<td>30-Jun-2022</td>
</tr>
<tr>
<td>08/2021</td>
<td>31-Jul-2022</td>
</tr>
<tr>
<td>09/2021</td>
<td>31-Aug-2022</td>
</tr>
<tr>
<td>10/2021</td>
<td>30-Sep-2022</td>
</tr>
<tr>
<td>11/2021</td>
<td>31-Oct-2022</td>
</tr>
<tr>
<td>12/2021</td>
<td>30-Nov-2022</td>
</tr>
<tr>
<td>01/2022</td>
<td>31-Dec-2022</td>
</tr>
<tr>
<td>02/2022</td>
<td>31-Jan-2023</td>
</tr>
</tbody>
</table>

For more information: [Home | CVDvaccine-US.com]
Vaccine Ordering and Distribution

Sai Teja Paruchuri, Vaccine Specialist
Reconciliation

Reconciliation – weekly

• Providers are required to reconcile and order covid vaccines during the ordering time frame: Tuesday through Monday.

• If a clinic doesn't reconcile COVID inventory for 14 days, they will not be able to create VFC & 317 vaccine orders.

• An informational video on COVID 19 vaccine reconciliation and ordering can be accessed at https://vimeo.com/528424790

• Inventory Reconciliation
Ordering Process: starting Aug 17
Minor change in delivery of orders with min quantities

• Providers can create orders in OSIIS during the ordering timeframe which is **Tuesday through Monday**.

• If an order is placed in OSIIS sometime between Tuesday May 3rd – Monday, May 9th, it will be processed and sent for fulfillment on Tuesday, May 10th.

• **Providers can order as much as they need. If less than the minimum quantity is required, you still need to order the minimum quantity and add a comment in the Clinic Comments text area indicating the number of doses needed.**

• For example, if you place an order for Pfizer 5-11 and Pfizer 12+ in the same order, and you wish to receive the minimum order quantity for Pfizer 12+ (300 doses) but only need 4 vials of Pfizer 5-11, please be sure to specify this information in the Clinic Comments.

• Providers now have the option to opt-out from receiving **Adult** vaccine ancillary kits with their vaccine order.
  • If you wish to opt-out, please specify this information in the Clinic Comments.
  • Please note: opt-out is ONLY available for adult vaccine formulations.

• Please do not refuse any vaccine shipments.
Ordering Process

- The cut-off to create orders in OSIIS – Monday, 5pm.
- To make any changes or cancellations to orders after the deadline, providers must reach out ASAP.
  - To request a change, a provider should email to OSDH VaccineHelp <VaccineHelp@health.ok.gov>
  - If provider doesn’t receive a confirmation of changes/cancellation within 24h, provider must call the OSDH Immunization Service 405.426.8580 to ensure that the order has been cancelled.
- Orders with at least min quantity, will be approved in OSIIS and directly shipped to providers – subjected to CHANGE depending on the available weekly threshold amounts.
- Orders with less than min quantity will be rejected in OSIIS with a note that County Health Department (CHD) will fulfill the order and get in touch with the provider via email or phone.
  - Example of the message: "Your order will be fulfilled by your County Health Department. Watch for e-mail communication about the process and phone calls to arrange vaccine transfer."
  - CHDs will deliver vaccines to providers on the same or the following week. Delivered by CHD employees, national guard, or courier service.
Ordering Process

• Upon delivery of the vaccine by CHD, provider should:
  1. Sign a Bill of Lading and keep a copy.
  2. Check that delivered vaccines are viable.
  3. Immediately place them into a storage according to the guidelines and label appropriately indicating expiration or/and Beyond-use dates (BUDs).
  4. Accept transfer in OSIIS.

• Questions about orders:
  • OSIIS: OSIISHELP@health.ok.gov
  • Vaccine ordering process: VaccineHelp@health.ok.gov
  • Order fulfillment/delivery: Contact CHDs (contacts will be shared in the follow-up email).
OSIIS Updates

Martin Lansdale, MPH
OSIIS Data Quality Coordinator
Moderna Booster in OSIIS

Administer

Vaccination Time

Administered By *

Refusal Reason *

Vaccine

COVID-19 mRNA (MOD)

Mfg | Lot | Exp Date (MM/DD/YY) | Funding Src | Inv Loc | NDC | Brand *

Dosage

Body Site *

Route *

0.25

Dosage

Refusal Reason
Pediatric Pfizer
Updating Passwords in OSIIS
Shot Records: Public Portal

- OSIIS has a public portal that can be found at the below link:
  - [https://osiis.health.ok.gov/osiis_public/Application/PublicPortal](https://osiis.health.ok.gov/osiis_public/Application/PublicPortal)
  - **DISCLAIMER:** Not all shots are recorded in OSIIS as reporting private vaccine is not required.

- Patients can search and download a copy of their shot record for just covid shots or their complete immunization history through the portal.

- The public portal uses **patient name, date-of-birth, email, and phone number** for verification purposes (all have to be on the shot record in OSIIS or patients cannot pull their shot record).

- Currently OSIIS has a high amount of missing emails/phone numbers.

- Providers need to make sure to document email and phone number for the patient **and add/send it to OSIIS** with the shot record in order to increase the likelihood of a records match in the portal.
"How To" Guides

- Moderna Booster OSIIS Guide
- How to Turn On User Default Order Notifications
- Inventory Reconciliation
- How to Place a Covid-19 Vaccine Order
- Immunizing a Patient for COVID
- How to add an extra dose
- Wastage
Questions/Suggestions
Personal Protective Equipment (PPE):
- [https://okppe.mybigcommerce.com/](https://okppe.mybigcommerce.com/)
- Proceed to the "Need an Account?" page and complete the Contact Us for an account.

Testing:
- Nasopharyngeal, throat, saliva
- [Testing@health.ok.gov](mailto:Testing@health.ok.gov)

Monoclonal Antibodies: (Amanda Cavner)
- [Antivirals@health.ok.gov](mailto:Antivirals@health.ok.gov)
- [https://oklahoma.gov/covid19/what-you-should-know monocolonal-antibody-therapies.html](https://oklahoma.gov/covid19/what-you-should-know/monocolonal-antibody-therapies.html)
Looking Forward

- Pandemic to Endemic
- Adult Immunization Coordinator
- Guest Speakers
QAs From Live Call
Resources/Tools

• OSIIS Training: https://osiis.health.ok.gov/osiis/Application/ApplicationHelp/Index